Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Lyell Immunopharma, Inc. (LYEL)

Lyell Immunopharma Q3 net loss widens to $45.5 million from $38.8 million

Negative Impact 3 of 5 earnings Written later

Lyell Immunopharma reported a third-quarter 2026 net loss of $45.5 million, up from $38.8 million a year earlier, as research and development expenses rose to $40.9 million. Cash, cash equivalents and marketable securities fell to $194.0 million from $247.2 million at December 31, 2025, and the company announced an $80.0 million private placement that it says will fund operations into 2028.

Key points

  • Q3 2026 net loss was $45.5 million versus $38.8 million in Q3 2025; the company attributed the increase mainly to higher R&D spending on clinical trial activity.
  • R&D expenses were $40.9 million versus $28.2 million, while G&A expenses fell to $9.3 million from $10.7 million.
  • Cash and marketable securities were $194.0 million at September 30, 2026, down from $247.2 million at December 31, 2025.
  • An $80.0 million private placement was announced in November 2026, with the company expecting cash to last into 2028.

The filing

CompanyLyell Immunopharma, Inc. (LYEL)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:14 PM ET
Accession number0001628280-26-070161

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.